Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languagesMPE, MyelomaApril 7, 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, MyelomaMarch 31, 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, MyelomaMarch 30, 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, MyelomaMarch 1, 2021
Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMIMPE, Patient evidenceFebruary 18, 2021
